Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar
The analysis evaluated 95 confirmed Covid-19 infections among the trial’s 30,000 participants. Moderna, which developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, said 90 cases of Covid-19 were observed in the placebo group versus 5 cases observed in the group that received its two-dose vaccine. That resulted in an estimated vaccine efficacy of 94.5%, it said.
Shares of the company jumped by more than 11% in premarket trading.
The announcement follows on the heels of similar news last week from Pfizer’s late-stage Covid-19 vaccine trial as pharmaceutical…